Phio Pharmaceuticals Corp
PHIO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.99M
Close$
$3.51
299.4% upside
Current Fair Value
299.4% upsideUndervalued by 299.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $9.99 Million |
|---|---|
| Enterprise Value | $-3,005,165.00 |
| Earnings per Share | $-1.45 |
| Beta | 0.84 |
| Outstanding Shares | 11,617,250 |
Return
| Return on Equity | -102.40% |
|---|---|
| Return on Assets | -90.19% |
| Return on Invested Capital | -18.92% |
Valuation & Multiples
| P/E Ratio | -0.64 |
|---|---|
| PEG | -0.7 |
| Price to Sales | - |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 1.19 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.36
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.34
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 5.55% |
|---|---|
| Total Invested | $2,063▼ 99.69% |
| Investors Holding | 2▼ 22.00% |
About Phio Pharmaceuticals Corp
10 employees
CEO: Gerrit Dispersyn
Phio Pharmaceuticals Corp. is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-...